Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04439799 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections
A Phase 4 study of Hypogonadism, Male, sponsored by University of Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT04439799 is a Phase 4 study of Hypogonadism, Male that has completed, run by University of Miami. The registered enrollment target is 81 participants, below the 106-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04439799, a Phase 4 study of Hypogonadism, Male, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate changes in vascular parameters and the prevalence of side effects in subjects receiving 1 cc (200mg) every 2 weeks intramuscular (IM) of Testosterone Cypionate versus subjects receiving 11mg three times daily (TID) Natesto to participant with clinical hypogonadism.
Conditions Studied
Interventions
- DRUG Testosterone Cypionate 200 Mg/ML
- DRUG Intranasal Testosterone
Study Locations (1)
Florida
- University of Miami Miller School of Medicine - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2020-08-07 |
| Est. Completion | 2023-02-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04439799
The ClinicalTrials.gov registry entry for NCT04439799 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (24% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypogonadism, Male appearing as the primary indexed condition, and to 2 interventions - of which Testosterone Cypionate 200 Mg/ML is the first listed.
NCT04439799 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04439799 about?
NCT04439799 is a clinical study titled "A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections". The purpose of this study is to evaluate changes in vascular parameters and the prevalence of side effects in subjects receiving 1 cc (200mg) every 2 weeks intramuscular (IM) of Testosterone Cypionate versus subjects receiving 11mg three times daily (TID) Natesto to participant with clinical hypogon...
What is the current status of trial NCT04439799?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2020-08-07. Estimated completion is 2023-02-09.
What conditions does trial NCT04439799 study?
This clinical trial studies the following conditions: Hypogonadism, Male.
What interventions are being tested in trial NCT04439799?
The interventions under investigation include: Testosterone Cypionate 200 Mg/ML (DRUG), Intranasal Testosterone (DRUG).
Who is sponsoring clinical trial NCT04439799?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04439799 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism, Male
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vogelxo(R) ABPM Study in Hypogandal Men
COMPLETED · Phase 4
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
-
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
RECRUITING · Phase 2
-
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
RECRUITING · Phase 3
-
Testosterone Treatment in Men with Chronic Kidney Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.